ZamifenacinAlternative Names: UK 76654
Latest Information Update: 31 Oct 1995
At a glance
- Originator Pfizer
- Mechanism of Action Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Irritable bowel syndrome